International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine

Consistent with the mission of the International Headache Society (IHS) to improve migraine management worldwide, this document focuses on providing practical recommendations on the preventive pharmacological management of migraine. Due to the inconsistent availability of medications across different regions of the globe, these recommendations are categorized into two levels: Optimal and Essential. The Optimal level is intended for settings where most drug treatments are available. The Essential level is focused on countries where only the drugs listed in the World Health Organization (WHO) Model List of Essential Medicines (EML) are available

Authors

Institutions

Publication Details

Journal
Cephalalgia
Published
2024-09-01
DOI
https://doi.org/10.1177/03331024241269735
Citations
85
Primary Topic
Migraine and Headache Studies
Type
article
Field-Weighted Citation Impact
32.77

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine

Amr Hassan, Mi Ji Lee, Tsubasa Takizawa, Francesca Puledda et al.
85 citations
Cephalalgia
Migraine and Headache Studies
32.77
article

International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine

Amr Hassan, Mi Ji Lee, Tsubasa Takizawa, Francesca Puledda, Andrea Cipriani, Jan Hoffmann, Teshamae Monteith, Esme Ekizoğlu, Rami Burstein, David García‐Azorín, Todd J. Schwedt, Haidar M. Al‐Khazali, Min Kyung Chu, Nicolas Vandenbussche, Shuu‐Jiun Wang, Hartmut Göbel, Hans‐Christoph Diener, Marco Lisicki, Janu Thuraiaiyah, María Teresa Goicochea, Patricia Pozo‐Rosich, Simona Sacco, Cristina Tassorelli, Eric Liebler, Gisela M. Terwindt, Marcio Nattan Portes Souza, Katharina Kamm, V.I. Romanenko, Daniele Martinelli, Aynur Özge, Yu‐Hsiang Ling, Raffaele Ornello, Mansoureh Togha, Sait Ashina, Alexandra Cocores, Koichi Hirata, Mário Fernando Prieto Peres, Freda Dodd-Glover, Bronwyn Jenkins, Shenguan Yu, Messoud Ashina
article en
85 citations

Abstract

Consistent with the mission of the International Headache Society (IHS) to improve migraine management worldwide, this document focuses on providing practical recommendations on the preventive pharmacological management of migraine. Due to the inconsistent availability of medications across different regions of the globe, these recommendations are categorized into two levels: Optimal and Essential. The Optimal level is intended for settings where most drug treatments are available. The Essential level is focused on countries where only the drugs listed in the World Health Organization (WHO) Model List of Essential Medicines (EML) are available

CephalalgiaVol. 44(9)
Universidad de Valladolid (ES), University of Copenhagen (DK), Beth Israel Deaconess Medical Center (US), Harvard University (US), Cairo University (EG), University of Miami (US), National Yang Ming Chiao Tung University (TW), Consejo Nacional de Investigaciones Científicas y Técnicas (AR), Universidad Nacional de Córdoba (AR), King's College London (GB), Yonsei University (KR), Keio University (JP), University of Pavia (IT), University of L'Aquila (IT), Severance Hospital (KR), Leiden University Medical Center (NL), Royal North Shore Hospital (AU), Ghent University Hospital (BE), Oxford Health NHS Foundation Trust (GB), Copenhagen University Hospital (DK), Rigshospitalet (DK), Seoul National University Hospital (KR), Chinese PLA General Hospital (CN), Taipei Veterans General Hospital (TW), Korle Bu Teaching Hospital (GH), Warneford Hospital (GB), LMU Klinikum (DE), Christian-Albrechts-Universität zu Kiel (DE), University of Oxford (GB), Sina Hospital (IR), AZ Sint-Jan (BE), Mayo Clinic Hospital (US), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR), International Headache Society (GB), Instituto de Investigación Médica Mercedes y Martín Ferreyra (AR), Oxford BioMedica (United Kingdom) (GB), Hospital Universitario Río Hortega (ES), Clinical Research Center Kiel (DE), Mersin Üniversitesi (TR), University of Duisburg-Essen (DE), Istanbul University (TR), Tehran University of Medical Sciences (IR), Dokkyo Medical University (JP)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Teva Pharmaceutical Industries, Handok, International Headache Society, Massachusetts Medical Society, Neuroscience Research Australia, American Headache Society, National Institute for Health and Care Research, University of Oxford, National Research Foundation, Deutsche Forschungsgemeinschaft, Yonsei University, Lundbeckfonden, Korea Health Industry Development Institute, National Research Foundation of Korea, Eisai, Astellas Pharma, H. Lundbeck A/S, Ipsen, Allergan, Pfizer Japan, Sanofi Genzyme, Eli Lilly Japan, Amgen Astellas Biopharma, Medical Research Council, Yonsei University College of Medicine, Daiichi Sankyo Europe
Openalex Percentile: Top 0%
Migraine and Headache Studies
32.77
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.